The successful targeting of immune checkpoints has revolutionized cancer treatment by reinvigorating the immune system’s ability to combat tumors, as evidenced by the clinical efficacy of anti-PD-1/PD-L1 and anti-CTLA-4 therapies (Jacquelot et al., 2019; Theivanthiran et al., 2020). Here, CD274 is linked to cancer.